Abstracts tagged "autoimmune diseases"

Abstract Number: 1355 • ACR Convergence 2023
Delivering Care for Pregnant Women with Rheumatic and Musculoskeletal Diseases in Ireland: Current Challenges and Practices
Rebecca O'Farrell¹, Sinead Maguire², Louise Moore³, Kieran Murray⁴, Áine Gorman⁵, Elisabeth Ball⁶, Claire Riddell⁶, Madeline O'Neill⁷, Natasha Jordan⁸, Barry O'Shea⁹, Douglas Veale¹⁰, Suzanne Donnelly¹¹, Grainne Murphy¹² and Gillian Fitzgerald¹³, ¹Department of Rheumatology, Galway, Dublin, Ireland, ²Toronto Western Hospital, Toronto, ON, Canada, ³Our Lady's Hospice and Care Services, Harold's Cross, Dublin 6W, Harold's Cross,, Ireland, ⁴University Hospital Limerick, Limerick, Ireland, ⁵Royal United Hospital, Bath, United Kingdom, ⁶Belfast Health and Social Care Trust, Belfast, United Kingdom, ⁷Our Lady's Hospice, Harold's Cross, Dublin, Ireland, ⁸Addenbrooke's Hospital, Cambridge, United Kingdom, ⁹St James's Hospital, Dublin, Ireland, ¹⁰St.Vincent's University Hosp, Dublin, Ireland, ¹¹Mater Misericordiae University Hospital, Dublin, Ireland, ¹²Cork University Hospital, Cork, Ireland, ¹³University Hospital Galway, Galway, Ireland
Background/Purpose: Rheumatic disease frequently affects women of childbearing age. Women with pre-existing rheumatic disease who are planning a pregnancy or develop these conditions during pregnancy…
Abstract Number: 1587 • ACR Convergence 2023
Mitochondrial Z-DNA and ZBP1 Drive Autoimmune Photosensitivity
Benjamin Klein, Mack Reynolds, Bin Xu, Mehrnaz Gharaee-Kermani, Amanda Victory, Shannon Loftus, Mary O'Riordan and J. Michelle Kahlenberg, University of Michigan, Ann Arbor, MI
Background/Purpose: Autoimmune photosensitivity is observed in type I Interferon (IFN) mediated diseases such as systemic and cutaneous lupus erythematosus (SLE/CLE) and dermatomyositis. Type I IFN…
Abstract Number: 1758 • ACR Convergence 2023
Identification of Circulating Autoantibodies Associated with ACPA Status in Early Rheumatoid Arthritis
Lucía Lourido¹, Vijay Joshua², Monika Hansson³, Ronald Sjöberg⁴, Elisa Pin⁴, Cristina Ruiz-Romero⁵, Peter Nilsson⁴, Lars Klareskog² and Francisco J. Blanco⁶, ¹Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006, A Coruña, Spain, ²Karolinska Institutet, Stockholm, Sweden, ³Division for Rheumatology, Department of Medicine (Solna) Karolinska Institutet, Stockholm, Sweden, ⁴Department of Protein Science, SciLifelab, KTH Royal Institute of Technology, Stockholm, Sweden, ⁵1) Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006, A Coruña, España. 4) Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN). Av. Monforte de Lemos, 3-5. Pabellón 11,28029, Madrid, Spain, ⁶Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain
Background/Purpose: Rheumatoid arthritis (RA) is associated with the presence of autoantibodies being the anti-citrullinated protein antibodies (ACPAs) the hallmark as they are present in almost…
Abstract Number: 1928 • ACR Convergence 2023
Response to Sars-Cov2 Vaccination in Rheumatic and Neurological Patients Treated with Different Immunosuppressive Therapies
Cristina Calomarde Gomez¹, Raquel Ugena García¹, Julia Valera², Melisa Mena², Maria Esteve², Irma Casas², jose Antonio Dominguez-Benitez², lidia Carabias-Ane², isaac Nuño-Ruiz², Cristina ramo-Tello², Javier Santesmases², Lourdes Mateo Soria³ and Melania Martinez Morillo¹, ¹Rheumatology department. Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ³HOSPITAL GERMANS TRIAS I PUJOL, Badalona, Spain
Background/Purpose: Vaccination against SARS-CoV2 has been the primary global strategy to prevent severe forms of this respiratory infection. However, multiple studies have shown that patients…
Abstract Number: 2102 • ACR Convergence 2023
Is This Prosthetic Joint Infected or Flaring?
Susan Goodman, Insa Mannstadt, Kathleen Tam, Alejandro Kochen, Lorien Shakib, Peter Sculco, Mark Figgie, Alberto Carli, Andy Miller, Linda Russell, Allina Nocon and Laura Donlin, Hospital for Special Surgery, New York, NY
Background/Purpose: Diagnosis of a periprosthetic joint infection (PJI) in a patient with inflammatory arthritis (IA) is challenging, as features of IA flares can mimic an…
Abstract Number: 2432 • ACR Convergence 2023
Wnt Signaling Drives Pathogenic Stromal Inflammation in Inflammatory Arthritis
Alisa Mueller¹, Angela Zou², Lucy-Jayne Marsh³, Samuel Kemble⁴, Saba Nayar³, Emily Taylor³, Triin Major³, David Gardner⁵, Gerald F.M. Watts¹, Cassandra Murphy¹, Roche Fibroblast Network Consortium⁶, Adam Croft³, Andrew Filer³, Christopher Buckley⁷, Kevin Wei⁸, ilya Korsunsky¹, Soumya Raychaudhuri¹ and Michael Brenner⁸, ¹Brigham and Women's Hospital, Boston, MA, ²Harvard Medical School, Boston, MA, ³University of Birmingham, Birmingham, United Kingdom, ⁴University Birmingham, Rugeley, United Kingdom, ⁵University of Birmingham, Havelock North, New Zealand, ⁶Roche, Basel, Switzerland, ⁷University of Oxford, Oxford, United Kingdom, ⁸Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Synovial fibroblasts are a promising therapeutic target in rheumatoid arthritis (RA) where they can adopt inflammatory or destructive phenotypes and directly promote bone and…
Abstract Number: 2572 • ACR Convergence 2023
Autoantibody Profile of Autoimmune Driven Interstitial Lung Disease as Compared to Idiopathic Pulmonary Fibrosis and Association of Autoantibodies with Survival
Elena Joerns¹, Chad Newton², Stanislav Kolenikov³, Jeffrey Sparks⁴ and David Karp⁵, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²UT Southwestern, Dallas, TX, ³NORC at the University of Chicago, Columbia, MO, ⁴Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ⁵UT Southwestern Medical Center, Dallas, TX
Background/Purpose: The term interstitial pneumonia with autoimmune features (IPAF) describes patients with interstitial lung disease (ILD) and features of autoimmunity, that do not fulfill classification…
Abstract Number: 0007 • ACR Convergence 2023
Targeting NF-κB Signalling in B Cells from ANCA-associated Vasculitis Impairs B Cell Biology as a Potential Novel Target
Ana Merino-Vico¹, Jan Piet van Hamburg¹, Paul Tuijnenburg¹, Aram Al-Soudi¹, Carlo Bonasia², Boy Helder¹, Abraham Rutgers², Wayel H. Abdulahad², Coen A. Stegeman², Jan-Stephan Sanders², Laura Bergamaschi³, Paul A. Lyons³, Theo Bijma², Laura Van Keep¹, Kirsten wesenhagen¹, Aldo Jongejan¹, Henric Olsson⁴, Niek De Vries¹, Taco W. Kuijpers¹, Peter Heeringa² and Sander Tas⁵, ¹Amsterdam University Medical Centers, Amsterdam, Netherlands, ²University Medical Center Groningen, Groningen, Netherlands, ³University of Cambridge, Cambridge, United Kingdom, ⁴AstraZeneca, Gothenburg, Sweden, ⁵Amsterdam UMC, locatie AMC, Utrecht, Netherlands
Background/Purpose: B cells have gained increased interest in ANCA-associated vasculitis (AAV) research, as the treatment of this autoimmune disease with rituximab (an anti-CD20 B cell…
Abstract Number: 0084 • ACR Convergence 2023
Excess IL-18 Protects from Experimental Autoimmune Encephalomyelitis Mainly via Preferential Augmentation of Suppressor/Regulatory over Autoreactive T-cell Function
Jeremy Morrissette¹, Vinh Dang², Jemy Varghese², Zachary Lanzar¹, Junior Nguyen², Emily Landy³, Anastasia Frank-Kamenetskii⁴ and Scott Canna², ¹University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³University of Pittsburgh, Pittsburgh, PA, ⁴CHOP/UPENN, Philadelphia, PA
Background/Purpose: Interleukin 18 (IL-18) is an inflammasome-activated cytokine that canonically amplifies interferon-gamma (IFNg) production and cytotoxicity by CD8 T-cells (CD8Ts) and Th1 CD4 T-cells (CD4Ts).…
Abstract Number: 0201 • ACR Convergence 2023
Tolerability and Safety of Recombinant Zoster Vaccine in Patients with Inflammatory Rheumatic Musculoskeletal Diseases – A Prospective Longitudinal Study over 12 Months
Ioana Andreica¹, Gianna Chierergo², Stefania Reale², Benjamin Wilde³, Styliani Tsiami⁴, David Kiefer⁴, Philipp Sewerin⁴, Hilal Kavruk⁵, Dimitra Karagkiozidou², Barbara Guminski⁴, Andreas Kribben³, Xenofon Baraliakos⁶, Juergen Braun⁴ and Uta Kiltz⁷, ¹Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ²Rheumazentrum Ruhrgebiet, Herne, and Ruhr-Universität Bochum, Herne, Germany, ³Department of Nephrology, University Hospital Essen, University Duisburg-Essen, Essen, Germany, ⁴Ruhr-Universität Bochum and Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Rheumazentrum Ruhrgebiet, Herne, and Ruhr-Universität Bochum, Düsseldorf, Germany, ⁶Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁷Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: Herpes zoster (HZ) is common in the elderly, with a lifetime risk of 25%. The primary risk factors for HZ are advanced age and…
Abstract Number: 0330 • ACR Convergence 2023
Patient-Reported Experiences and Comorbidities in Patients with IgG4-Related Disease with and Without Pancreatic Involvement
Liam Harvey¹, Guy Katz², Yasmin Hernandez-Barco², Ana Fernandes², Aubree McMahon², Grace McMahon², Isha Jha², Zachary Wallace³, Cory Perugino² and John Stone⁴, ¹Frank H. Netter School of Medicine at Quinnipiac University, New Haven, CT, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Newton, MA, ⁴Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA
Background/Purpose: IgG4-Related Disease (IgG4-RD) is a systemic immune-mediated disease that commonly involves the pancreas in the form of autoimmune pancreatitis (AIP). Despite being one of…
Abstract Number: 0555 • ACR Convergence 2023
Evaluation and Management of the “False Positive” ANA and Undifferentiated Connective Tissue Disease Amongst Rheumatologists
Neha Gupta¹, Sarah Ford², Lane Scheiber², Tangada Rao² and Abhishek Nandan², ¹Virginia Commonwealth University Health Systems, Richmond, VA, ²Virginia Commonwealth University Health Systems; Veterans Affairs Medical Center, Richmond, VA
Background/Purpose: The management of a positive anti-nuclear antibody (ANA) is one of the most common consultations in rheumatology outpatient practice. The prevalence of a positive…
Abstract Number: 0798 • ACR Convergence 2023
A Novel 3D Model of Rheumatoid Arthritis Synovial Tissue Incorporating Fibroblasts, Endothelial Cells and Macrophages
Eva Philippon¹, Lisanne van Rooijen¹, Jan Piet van Hamburg¹, Fatemeh Khodadust¹, Conny Van der Laken² and Sander Tas³, ¹Amsterdam University Medical Centers, Amsterdam, Netherlands, ²Amsterdam UMC - location VUMC, Amsterdam, Netherlands, ³Amsterdam UMC, locatie AMC, Utrecht, Netherlands
Background/Purpose: Rheumatoid Arthritis (RA) is a progressive and systemic autoimmune disorder associated with chronic and destructive inflammation of the joints. The hallmarks of RA are…
Abstract Number: 0996 • ACR Convergence 2023
Will Patients Engage with Digital Technologies as Part of Routine Healthcare?
Jeffrey R Curtis¹, Sandeep Sodhi², Yuji Su³, Scott Laster⁴, Fenglong Xie², Ye Liu⁵ and Corey Patrick⁴, ¹Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, ²Illumination Health, Hoover, AL, ³University of Alabama at Birmingham and Illumination Health, Birmingham, AL, ⁴Micare, Memphis, TN, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Remote Physiologic Monitoring (RPM) and Remote Therapeutic Monitoring (RTM) are new care delivery options by which patients can provide data to their provider via…
Abstract Number: 1128 • ACR Convergence 2023
Refractory Inflammatory Ocular Pathology and Treatment with Janus Kinase Inhibitors. Multicenter Study and Literature Review
Carmen Lasa-Teja¹, Lara Sanchez-Bilbao², Jose Luis Martin-Varillas³, Vanesa Calvo Río⁴, José Luis Álvarez-Vega⁵, Emma Beltran-Catalan⁶, María del Mar Esteban-Ortega⁷, Santiago Muñoz⁷, Olga Maiz⁸, Ignacio Torre-Salaberri⁹, Ana Urruticoechea¹⁰, Elia Valls-Pascual¹¹, Raúl Veroz¹², Carmen Alvarez Reguera¹³, Rosalía Demetrio¹³ and Ricardo Blanco¹⁴, ¹Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology Group, Santander, Spain, ²Hospital Universitario Marques de Valdecilla, Santander, Spain, ³Hospital de Laredo, Laredo, Spain, ⁴Valdecilla Hospital, Santander, Spain, ⁵Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, ⁶HOSPITAL DEL MAR, Barcelona, Spain, ⁷Hospital Infanta Sofia, Madrid, Spain, ⁸Hospital Universitario de Donostia. San Sebastián, Spain., Donosti, Spain, ⁹Hospital Universitario de Basurto, Bilbao, Spain, ¹⁰Hospital Can Misses, Ibiza, Spain, ¹¹Hospital Universitario Doctor Peset. Alicante, Spain., Valencia, Spain, ¹²Hospital de Mérida, Mérida. Spain., Mérida, Spain, ¹³Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Inflammatory ocular pathology (IOP) includes internal (uveitis) and external [mainly ocular surface pathology such as epi/scleritis and peripheral ulcerative keratitis (PUK)] involvement. IOP may…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.